Die Vorlaufzeit zur Produktion der Tests , in ausreichender Menge, müsste vorbei sein !.
Source: Calypte Biomedical Corporation
Posted: 17th May, 2004
Calypte Contracts Out Manufacture of Kits for Asia
Calypte Biomedical Corporation who develop, manufacture and market HIV diagnostic tests, have announced a non-exclusive contract manufacturing agreement with Pacific Biotech Co. Ltd., a Thai diagnostics company located in Phetchaboon.
Pacific Biotech will be making Calypte's rapid blood test for HIV-1+2 antibodies. This is the first rapid HIV test from Calypte to go into production at Pacific Biotech, and is seen the first in a series of such technology transfers. The products manufactured at this facility are primarily intended to serve markets in Asia, excluding China, and Africa. The test is ideally suited to developing countries as it based on a urine sample so no blood drawing is required.
Calypte Enters Into Memorandum of Understanding with Beijing Tiantan Biological Products
ALAMEDA, Calif., May 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (CYPT) , a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it is has selected Beijing Tiantan Biological Products Co., Ltd. ("BTBP") as its manufacturing partner in China. Under a memorandum of understanding, the parties expect to share technology and equipment to produce Calypte's Rapid HIV-1/2 Antibody Tests in China.
Calypte shall be responsible for supplying technology, manufacturing and quality control equipment and expertise, technical assistance and technical support, while BTBP shall supply the manufacturing facilities where the HIV rapid tests will be produced. Calypte will be in charge of day-to-day operations.
"We are very pleased that this memorandum of understanding whereby BTBP established the long-term cooperation relationship with Calypte and the new cooperation company will manufacture Calypte's HIV rapid products, as BTBP sees a great market potential for Calypte's rapid HIV-1/2 antibody tests in the People's Republic of China, as well as other parts of the world," said Mr. Ni Daoming, BTBP's Board Chairman.
"Our relationship with BTBP is expected to greatly accelerate our entry into the Chinese market," said Dr. J. Richard George, President and CEO of Calypte. "BTBP is one of the leading Chinese companies in the field of biological products and has a vast amount of experience in building and operating Good Manufacturing Practices (GMP) compliant facilities and obtaining regulatory approvals. We will draw upon their experience in these vital areas.
"BTBP, acting on good faith that this memorandum of understanding will lead to a definitive agreement, has met with our technical personnel, jointly defined the needs of the facility and has begun construction of the manufacturing site", Dr. George continued. "This cooperation will enable us to stay on a fast-track by continuing facility construction during the negotiations of a final agreement."
About BTBP:
Beijing Tiantan Biological Products Co. Ltd. is a biotech company listed on the Shanghai Stock Exchange (601161.SS) with a current market capitalization in excess of $300 million (US). The company manufactures multiple vaccines for both viral and bacterial infections. BTBP is the Special Vehicle Company approved for listing on the Shanghai Stock Exchange; the parent company is National Vaccine & Serum Institute who currently owns over 66% after two private placements of the BTBP's shares, including 25 million public shares issued in 2003.
Zurück
Weiter
